In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia
Authors:
- Johanne BlaisJBJohanne Blais
- Stacey R. LewisSLStacey R. Lewis
- Christopher S. LundeCLChristopher S. Lunde
- Steven L. BarriereSBSteven L. Barriere
- H. David FriedlandHFH. David Friedland
- Michael M. KittMKMichael M. Kitt
- Bret M. BentonBBBret M. Benton
- 1 December 2012
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 74 (4) , 429-431
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)International Journal of Antimicrobial Agents, 2011
- Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial PneumoniaClinical Infectious Diseases, 2010
- Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemiaJournal of Antimicrobial Chemotherapy, 2010
- Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid IIAntimicrobial Agents and Chemotherapy, 2009
- Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia modelJournal of Antimicrobial Chemotherapy, 2009
- Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram‐Positive InfectionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance InitiativeJournal of Antimicrobial Chemotherapy, 2008
- Changes in the Epidemiology of Methicillin-Resistant Staphylococcus aureus in Intensive Care Units in US Hospitals, 1992-2003Clinical Infectious Diseases, 2006
- Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2005